Colossal is spinning out a dozen companies each with massive potential
Predictor: Peter Diamandis · ep#245 "AI + Synthetic Biology: The Most Transformative Technology in Human History | Ben Lamm (Colossal)" · source
Prediction text
Colossal is spinning out a dozen companies each with massive potential | so colossal as a parent company is spinning out a dozen companies each of which have massive potential
Verbatim quote
so colossal as a parent company is spinning out a dozen companies each of which have massive potential
Predictor: Peter Diamandis
Calibration plot (stated vs observed)
Evidence about this node from Peter Diamandis is multiplied by κ in /api/intake. Lower κ = less weight; floors at 0.10 (effectively silenced) and caps at 1.00 (full weight).
Reference class
This node isn't linked to a reference class. The Bayesian update applies without outside-view blending.
Probability over time
Milestone chain
- 2024-12-31hitColossal spins out Breaking (plastic degradation) and Form Bio (computational biology)How: Colossal has spun out >=2 standalone companies that have raised independent seed/Series A fundingSource: https://en.wikipedia.org/wiki/Colossal_Biosciencesconf 99%Notes: HIT — Breaking ($10.5M seed for plastic degradation) + Form Bio ($30M for compbio platform) spun out and funded independently.
- 2025-01-15hitColossal raises $200M Series C at $10.2B 'decacorn' valuationHow: Colossal Biosciences closes >=$150M funding round at >=$8B post-money valuationSource: https://techcrunch.com/2025/01/15/colossal-biosciences-raises-200m-at-10-2b-valuation-to-bring-back-woolly-mammoths/conf 99%Notes: HIT — $200M Series C from TWG Global at $10.2B valuation; ~7x jump from $1.5B prior round.
- 2025-01-15hitColossal officially announces plan for 3 additional spinouts (incl. artificial womb tech)How: Colossal CEO/founders publicly disclose plan to spin out >=3 additional businesses including artificial womb technology ventureSource: https://techcrunch.com/2025/01/15/colossal-biosciences-raises-200m-at-10-2b-valuation-to-bring-back-woolly-mammoths/conf 95%
- 2026-03-31hitAstromech (Colossal spinout) emerges from stealth at $2B valuationHow: Astromech publicly emerges from stealth — $10.5M raise, $2B valuation — as Colossal spinoutSource: https://www.dmagazine.com/business-economy/2026/03/ben-lamm-astromech-colossal/conf 95%Notes: HIT — Astromech is the latest of Colossal's announced spinouts (Form Bio, Breaking, Astromech)
- 2026-10-20pendingQ1 window check-in (25%)
- 2026-06-01 → 2027-12-31pendingColossal spinout count reaches 6+ companiesHow: Colossal has 6+ active spinout companies with independent corporate structureSource: https://en.wikipedia.org/wiki/Colossal_Biosciencesconf 55%Notes: Diamandis claim is 'a dozen' — 6+ midpoint check. 2 confirmed + 3 announced = 5 baseline.
- 2027-04-12pendingQ2 window check-in (50%)
- 2026-09-01 → 2027-12-31pendingColossal announces 4th-6th spinout under 'dozen companies' planHow: Colossal Biosciences publicly announces ≥3 additional spinouts (beyond Form Bio, Breaking, Astromech)Source: https://www.pharmavoice.com/news/dire-wolves-colossal-ben-lamm-pharma-drug-form-bio/802526/conf 70%
- 2026-09-01 → 2027-12-31pendingColossal raises follow-on at ≥$15B valuationHow: Colossal Biosciences closes funding round at ≥$15B post-money (vs $10.2B in Jan 2026)Source: https://en.wikipedia.org/wiki/Colossal_Biosciencesconf 60%
- 2026-09-01 → 2028-03-31pendingForm Bio reaches $100M ARR or $1B valuation milestoneHow: Form Bio publicly reports ≥$100M ARR or raises round at ≥$1B valuationSource: https://venturebeat.com/ai/colossal-biosciences-spins-off-form-bio-software-for-computational-life-sciences-breakthroughsconf 55%
- 2026-09-01 → 2028-06-30pendingBreaking (plastic-degradation spinout) commercial pilot launchedHow: Breaking announces commercial pilot of X-32 microbe with municipal/industrial customerSource: https://www.pharmavoice.com/news/dire-wolves-colossal-ben-lamm-pharma-drug-form-bio/802526/conf 55%
- 2027-10-02pendingQ3 window check-in (75%)
- 2027-01-01 → 2028-12-31pendingFirst Colossal spinout reaches IPO or >=$1B unicorn valuationHow: One Colossal spinout (Form Bio, Breaking, womb tech, or future) reaches IPO or independent unicorn ($1B+) valuationSource: https://pitchbook.com/profiles/company/481220-47conf 40%Notes: Cascade — 'massive potential' claim only validated by exit-stage outcomes.
- 2028-12-31pendingColossal spinout count reaches 12 companies (Diamandis claim)How: Colossal has >=12 spinout companies with independent funding by Diamandis horizon endSource: https://www.diamandis.com/blog/abundance-37-no-human-codersconf 30%Notes: Cascade — Diamandis (host of source episode) claims 'a dozen.' Actually disclosed plan = 5. Some are 'top secret' per the verbatim. 12 is aggressive.
What if this resolves?
Click a button to clamp this prediction and run a Gibbs sample. Returns the predictions whose marginals shift most. ~30s per run; ideal for stress-testing "if X resolves, what else moves?"
Evidence chain
Show missed milestones
- LLR -0.693 · moderate · expected 2024-12-31Colossal spins out Breaking (plastic degradation) and Form Bio (computational biology)
- LLR -0.693 · moderate · expected 2025-01-15Colossal raises $200M Series C at $10.2B 'decacorn' valuation
Network propagation neighbors
Top incoming (parents)
Edges that influence THIS node's belief
| Kind | Node | Their prob | P(c|s=T) | P(c|s=F) | Δ implied |
|---|---|---|---|---|---|
| killer | TK13 Biotech/Synbio Safety Event | 15.0% | 0.050 | 0.650 | +0.019 |
Top outgoing (children)
Predictions THIS node influences
No outgoing edges.
Ticker exposure
Beneficiaries (19)
Adverse (4)
Prerequisites (1)
| Type | Pred | Title | Domain | Lag |
|---|---|---|---|---|
| killer | TK13 | Biotech/Synbio Safety Event | — | — |
Dependents (0)
| Type | Pred | Title | Domain | Lag |
|---|---|---|---|---|
| No dependents | ||||
Expected milestones (6)
| Expected by | Description | Status |
|---|---|---|
| 2024-12-31 | Colossal spins out Breaking (plastic degradation) and Form Bio (computational biology) | missed |
| 2025-01-15 | Colossal raises $200M Series C at $10.2B 'decacorn' valuation | missed |
| 2026-06-30 | Colossal officially announces plan for 3 additional spinouts (incl. artificial womb tech) | pending |
| 2027-12-31 | Colossal spinout count reaches 6+ companies | pending |
| 2028-12-31 | Colossal spinout count reaches 12 companies (Diamandis claim) | pending |
| 2028-12-31 | First Colossal spinout reaches IPO or >=$1B unicorn valuation | pending |
Raw metadata
{
"nia": false,
"qty": "A dozen companies",
"url": "https://www.youtube.com/watch?v=Goa6c6Qz__I",
"mode": "PREDICTION",
"role": "Host",
"caveats": "Some are top secret",
"context": "colossal as a parent company is spinning out a dozen companies each of which have massive potential",
"verbatim": "so colossal as a parent company is spinning out a dozen companies each of which have massive potential",
"conv_cues": "is spinning out",
"direction": "HAPPEN",
"timeframe": "Near future",
"conv_level": "HIGH",
"milestones": [
{
"kind": "llm_pre_event",
"label": "Colossal spins out Breaking (plastic degradation) and Form Bio (computational biology)",
"notes": "HIT — Breaking ($10.5M seed for plastic degradation) + Form Bio ($30M for compbio platform) spun out and funded independently.",
"source": "https://en.wikipedia.org/wiki/Colossal_Biosciences",
"status": "hit",
"weight": 0.4,
"ordinal": -13,
"source_id": null,
"confidence": 0.99,
"source_url": "https://en.wikipedia.org/wiki/Colossal_Biosciences",
"expected_date": "2024-12-31",
"observed_date": "2024-12-31",
"research_origin": "deep_research",
"measurement_criterion": "Colossal has spun out >=2 standalone companies that have raised independent seed/Series A funding"
},
{
"kind": "llm_pre_event",
"label": "Colossal raises $200M Series C at $10.2B 'decacorn' valuation",
"notes": "HIT — $200M Series C from TWG Global at $10.2B valuation; ~7x jump from $1.5B prior round.",
"source": "https://techcrunch.com/2025/01/15/colossal-biosciences-raises-200m-at-10-2b-valuation-to-bring-back-woolly-mammoths/",
"status": "hit",
"weight": 0.4,
"ordinal": -12,
"source_id": null,
"confidence": 0.99,
"source_url": "https://techcrunch.com/2025/01/15/colossal-biosciences-raises-200m-at-10-2b-valuation-to-bring-back-woolly-mammoths/",
"expected_date": "2025-01-15",
"observed_date": "2025-01-15",
"research_origin": "deep_research",
"measurement_criterion": "Colossal Biosciences closes >=$150M funding round at >=$8B post-money valuation"
},
{
"kind": "llm_pre_event",
"label": "Colossal officially announces plan for 3 additional spinouts (incl. artificial womb tech)",
"source": "https://techcrunch.com/2025/01/15/colossal-biosciences-raises-200m-at-10-2b-valuation-to-bring-back-woolly-mammoths/",
"status": "hit",
"weight": 0.4,
"ordinal": -11,
"source_id": null,
"confidence": 0.95,
"source_url": "https://techcrunch.com/2025/01/15/colossal-biosciences-raises-200m-at-10-2b-valuation-to-bring-back-woolly-mammoths/",
"expected_date": "2025-09-30",
"observed_date": "2025-01-15",
"research_origin": "deep_research",
"expected_date_range": {
"to": "2026-06-30",
"from": "2025-01-01"
},
"measurement_criterion": "Colossal CEO/founders publicly disclose plan to spin out >=3 additional businesses including artificial womb technology venture"
},
{
"kind": "llm_pre_event",
"label": "Astromech (Colossal spinout) emerges from stealth at $2B valuation",
"notes": "HIT — Astromech is the latest of Colossal's announced spinouts (Form Bio, Breaking, Astromech)",
"source": "https://www.dmagazine.com/business-economy/2026/03/ben-lamm-astromech-colossal/",
"status": "hit",
"weight": 0.4,
"ordinal": -10,
"source_id": null,
"confidence": 0.95,
"source_url": "https://www.dmagazine.com/business-economy/2026/03/ben-lamm-astromech-colossal/",
"expected_date": "2026-03-31",
"observed_date": "2026-03-31",
"research_origin": "deep_research",
"measurement_criterion": "Astromech publicly emerges from stealth — $10.5M raise, $2B valuation — as Colossal spinout"
},
{
"kind": "quartile_checkpoint",
"label": "Q1 window chec
... (truncated)